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Foreword 
Dear Colleagues 
I am pleased, on behalf of the EuroScan International Network, to present you with 
the second edition of “A toolkit for the identification and assessment of new and 
emerging health technologies”. This work has been contributed to by all members of 
EuroScan. Whilst this document has been updated to assist members, it is also 
publicly available to any organisation that wishes to undertake early assessment and 
alert activities. These activities apply to the early life cycle of a technology; providing 
timely information when technologies are emerging, that is prior to adoption, or they 
are new, that is in the early phase of adoption. This relates to the sequence of 
developing technologies from basic biomedical research through to clinical use.  
Health systems have a need for this type of activity and the information generated, as 
many technologies are introduced into the healthcare system before a formal health 
technology assessment is available. EuroScan aims to support the development of 
methods that result in an output that meets the needs of a variety of organisations 
including healthcare commissioners, decision makers, research funders and 
organisations planning the evaluation of emerging technologies.   
I commend this updated second edition of the toolkit to you and thank all members of 
Euroscan and Euroscan Secretariat in the University of Birmingham for their 
contribution. 
 
Yours sincerely 
 
Professor Brendon Kearney 
Chair, Euroscan International Network 
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Executive summary 
The first toolkit for the identification and assessment of new and emerging health 
technologies was developed by members of the EuroScan International Network and 
published in 2009. Five years later this revised toolkit continues to focus on methods that are 
integral to an early awareness and alert (EAA) system. It is once again a collaborative piece 
of work to which all members have contributed with new information based on their 
experiences being added. 
The main stages involved in EAA systems continue to be: identification of information on new 
and emerging technologies (horizon scanning); filtration and prioritisation of the identified 
information; and assessment of the technology or group of technologies. The toolkit provides 
guidance on these stages and highlights the various approaches that can be taken at each of 
these stages depending on the context of the EAA system and resources available.  
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Introduction 
EuroScan – the International Information Network on New and Emerging Health 
Technologies is a collaborative network of member agencies for the exchange 
of information on important new and emerging health technologies (including 
drugs, devices, diagnostics, procedures, programmes and settings).  
EuroScan International Network is the leading global collaborative network that 
collects and shares information on innovative technologies in health care in 
order to support decision making and the adoption and use of effective, useful 
and safe health-related technologies. The network is also the principal global 
forum for the sharing and development of methods for the early identification 
and early assessment of new and emerging health-related technologies and 
predicting their potential impact on health services and existing technologies. 
EuroScan International Network is committed to work with a high level of 
transparency and professionalism, and in partnership with researchers, 
research centres, governments and international organisations to produce high 
quality information and effective early awareness and alert (EAA) systems for 
our respective constituencies. EuroScan is also committed to support the 
development of existing and new not-for-profit public agencies working in the 
EAA field. 
The goals of the EuroScan International Network are: 
 To establish a system to share skills and experience in EAA activities.  
 To strengthen activities for the development of methodological approaches 
for the identification, description and assessment of new or emerging health 
technologies.  
 To improve the exchange of information about new and emerging health 
technologies and their potential impact on health services and existing health 
technologies.  
 To increase the impact of EuroScan International Network’s output.  
 To identify relevant not-for-profit public partners in order to share the results 
of work with partners/members of the EuroScan International Network 
collaboration.  
 To advise not-for-profit organisations within public administrations who wish 
to consider the establishment of EAA activities.   
One of the ways EuroScan members are contributing to achieving these goals 
is by sharing their experiences of managing and conducting EAA activities in 
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this Methods Toolkit. The toolkit was originally published in 2009 but has been 
reviewed and revised by EuroScan members to incorporate the latest 
approaches, and findings of research, to inform methods development. 
Each member agency is unique in the way it approaches its work but all have a 
common goal of informing their customers about new and emerging health 
technologies that may have a significant impact on their health system. 
Appendix 1 lists EuroScan member agencies. 
This document outlines the methods that members of EuroScan employ to 
identify, select and evaluate relevant new and emerging health technologies. It 
is aimed at those interested in establishing or improving an EAA system. All 
members of EuroScan have contributed to the content to ensure different 
healthcare systems, contexts and methods are represented. 
The remainder of this document introduces the reader to EAA systems; gives 
guidance on the different stages involved in EAA activities; and provides 
questions that anyone establishing or improving an EAA system should ask 
themselves or pose to others. There is also a checklist that takes you through 
each stage involved in early warning and alert activities (Appendix 8) and a list 
of additional reading materials (Appendix 7). 
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Early awareness and alert systems  
EAA systems are also known as early warning systems or horizon scanning 
systems (Appendix 2 – Glossary). They aim to identify, filter and prioritise new 
and emerging health technologies; to assess or predict their impact on health, 
costs, society and the healthcare system; and to inform decision makers and 
research planners.  
EAA systems can be located in individual agencies providing information to a 
defined customer or a range of customers. They can also be networks of 
agencies (within a country e.g. regions collaborating in a network, or 
internationally) working towards the same goal. The benefits of networks are 
well documented and form the basis for the development of the EuroScan 
International Network (www.euroscan.org.uk). Examples of EAA networks 
include the Canadian Network for Environmental Scanning in Health (CNESH) 
and the Grupo de Evalucion de nuevas Technologia Sanitarias (GEnTECS) 
(Appendix 3). 
EAA activities are part of a continuum of HTA activities that ranging from 
primary basic scientific research, evidence of safety and efficacy (e.g. drug 
licensing), evidence reviews & early assessments, full HTAs and pragmatic 
trials of a technology in widespread use (Figure 1). From the beginning to the 
end of this continuum there is a shift from industry to publicly funded research. 
 
Figure 1 The Continuum of HTA Activities 
General 
clinical use 
Basic 
biomedical 
research 
Translational 
research 
Safety and 
efficacy 
Effectiveness 
and cost- 
effectiveness 
Primary data collection 
Horizon scanning  
(early awareness and 
alert activities) 
Full HTAs and 
Cochrane style reviews 
Pragmatic trials 
Reviews and early assessments 
Market Access 
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Main stages involved in EAA systems 
EAA systems incorporate all or the majority of the stages outlined in Figure 2. 
 
Figure 2 Stages involved in an early awareness and alert system 
Identify your 
market/ 
customers 
Determine your 
time horizon 
Horizon Scanning/ 
Identification 
Prioritisation 
Dissemination 
Filtration 
Updating 
information 
Peer review 
Peer review 
 
 
Assessment 
Meets criteria 
Does not meet 
criteria 
Evaluation of 
activities and system 
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Benefits of implementing an EAA System 
An EAA system ensures that there is a systematic approach to identifying 
important new and emerging health technologies. They also ensure that 
technologies are considered for evaluation at the right time, before widespread 
diffusion, thus protecting patients from ineffective and potentially unsafe health 
technologies and supporting the uptake of innovative, cost effective health 
technologies. EAA systems alert policy makers and health service organisations 
to health technologies that could change current options or decisions; require 
revision of current guidelines; and/or require further planning or commissioning 
of activities, e.g. research. Advance notice of an emerging technology can 
ensure processes are put in place to support and monitor clinical development. 
For ‘lower-profile’ technologies, for example those aimed at treating less 
prevalent conditions, EAA systems can raise awareness thus facilitating the 
development and adoption process. 
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Stage 1: Identify your customers  
The first step in developing an EAA system is to clearly define who the target 
audience will be and what the objective is for the activity. Even though this may 
sound obvious, this is decisive in developing the methods appropriate to the 
system. A system may have several customers or users with differing needs. 
 
Questions to answer 
 What is the purpose of your EAA system? 
EAA systems can be used to identify a wide range of new and emerging 
health technologies that may need to be considered for further evaluation or 
a full health technology assessment (HTA). The information on emerging 
health technologies can also be used to inform gaps in research activities 
and requirements for primary research. Information from EAA systems can 
assist HTA agencies, academic institutions, government departments and 
others to plan their work and their resource requirements.  
 Who do you intend to inform? 
 This will be health system dependent. You should always keep in mind the 
characteristics of the system you are informing (e.g. the population it 
serves, availability of resources, knowledge and skills of professionals, 
disease areas covered). 
 Types of stakeholders that might be informed by the system include policy 
makers, commissioners, purchasers, healthcare professionals, healthcare 
providers, reimbursement agencies, HTA agencies, commissioners of 
research, patients and patient organisations. 
 The information could be used by, or targeted at, different levels within 
your country i.e. national, regional, local users. 
 
EAA activities in a hospital setting are discussed briefly in Appendix 4. 
 
 What does your customer expect from you (and what not)? 
It is important to agree on expectations, for example: 
 Volume and format of output. 
 Frequency and timing of reports e.g. in relation to fixed dates for decision 
making. 
EuroScan - International Network 
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 Availability: confidential, limited availability or publicly available. 
 Different products may be required depending on different customers’ 
needs. 
 What type of output and information is needed? 
 Content – a brief overview of a technology or a full assessment. 
 Size of documents - a 1-2 page summary, or a lengthier review. 
 Style of documents - written, for example, as a formal report or a 
newsletter. 
 Format – paper, electronic. 
 Data - confidential information retrieved from manufacturers or only 
publicly available information sources. 
 What is the scope of your EAA system? Methods will vary depending on 
whether there is interest in one or more of the following: 
 Pharmaceuticals 
 Devices 
 Diagnostics 
 Surgical interventions 
 Medical procedures 
 Hospital care 
 Community care/ programmes 
 Public health interventions 
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Stage 2: Determine your time horizon  
Questions to answer: 
 When does your customer want information?  
The timing of an output will depend on the purpose of the EAA system and 
the customer you are informing but may also depend on the technology type.  
Information may be required at various points in a technology’s life-cycle: 
 several years before the technology enters the healthcare system, 
 when it is about to be launched,  
 at the time when the technology is introduced into the healthcare system 
or has recently launched,  
 has been launched but is diffusing slowly, or  
 when there is a change in indication or use of the technology.  
 
 What is the expected time-frame for a technology to enter the healthcare 
system? 
This will vary depending on technology type and its characteristics: 
 The development and regulation pathways for pharmaceuticals are well 
defined so it is often easier to determine the expected time-frame than it is 
for other technologies. 
 It can be difficult to determine the stage of development of diagnostics and 
medical devices. These technologies may have a conformity mark (e.g. 
CE mark) but can still be in varying stages of development. In addition, 
developments in these technologies may be continual so it is not always 
obvious which version of the technology you are considering.   
 For some new areas of technology development, e.g. cellular therapies, 
the development and regulatory pathway is more complex and may impact 
on time to enter the healthcare system. 
 Public health interventions and programmes are often developed on a 
small scale without a regulatory pathway, and may enter the healthcare 
system initially in one area before being adopted on a wider scale, if at all. 
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Stage 3: Horizon scanning 
(Identification)  
Horizon scanning is the systematic identification of new and emerging health 
technologies that have the potential to impact on health, health services, and/or 
society; and which might be considered for an HTA. 
 
Identification can be: 
 Proactive: where a range of sources are searched for information on new 
and emerging health technologies. 
 Reactive: where systems are in place that allow stakeholders, health 
professionals, developers and/or consumers to inform the EAA system on 
new and emerging health technologies. 
The former is more resource intensive; the latter may not be as inclusive. A 
combination of both can be used. 
A system needs to be in place to collect and allow management of the 
information gathered during identification. Constructing a database of identified 
technologies with additional information fields, such as where the technologies 
were sourced, is recommended. 
 
Identification sources  
The EAA system needs to determine which sources will be scanned. This will 
depend on the answers to the questions in stages 1 and 2, and resources 
available. Appendix 5 provides examples of identification sources used by 
EuroScan member agencies. It is worth noting that the list is not exhaustive or 
static; new identification sources are regularly being discovered. 
 Identification sources should be reviewed periodically to assess their 
usefulness i.e. yielding topics, or providing sufficient yield for cost of 
subscription or if different sources are required. 
 Existing specialized horizon scanning databases, e.g. EuroScan, can be 
consulted if your EAA system does not have the resources to scan 
proactively. 
 Many sources can be scanned online and regular email alerts can be 
subscribed to, often free of charge. 
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 Frequency of scanning will depend on the source. Email alerts can be sent at 
regular intervals usually daily or weekly, paper publications are generally less 
frequent (weekly or monthly) and some sources may only need scanning 
annually, for example, conference proceedings. 
 
Types of identification sources 
 Primary sources – information is obtained directly from sources closest to the 
technology. 
 Secondary sources - information is obtained from sources that have used 
primary sources but may have edited or filtered the information.  
 Tertiary sources – information is obtained from sources that have prioritised 
the information themselves and perhaps carried out an assessment. 
 
 
New or emerging 
health 
technologies 
Figure 3 – Examples of potential identification sources 
Commercial 
media 
Trial 
registries 
Clinical 
experts 
General 
media 
Commercial 
developers 
Patients  
and public 
Medical 
media 
Scientific 
journals 
Other horizon 
scanning 
organisations 
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Primary Sources 
Commercial developers – pipeline information 
Pipeline information may come from: 
 Direct contact with commercial developers.  
 Indirect information from commercial developers – websites, annual reports, 
press releases, conference presentations. 
 Market analysts, consultants, and other commercial research organisations. 
 Commercial pharmaceutical and other specialist health technology media. 
 Commercial pharmaceutical and other health technology databases. 
 
Potential issues for identification 
 Incomplete, partial, inaccurate or uncertain information (especially indications 
& time to licensing, market authorization or launch). 
 Lack of communication, some companies will not exchange information. 
 Industry confidence in the EAA system, particularly dealing with commercial 
in-confidence information. 
 Clarity about role and processes of EAA system. 
 Conflict of interest and/or vested interests. 
 
Clinical trial registers 
There are a number of official platforms available for registering a clinical trial 
e.g. ClinicalTrials.gov and WHO International Clinical Trials Registry (WHO 
ICTRP). Some countries require clinical trials conducted in their country to be 
registered whereas others do not. For identification purposes trial registers can 
be searched by disease area or condition, and technology type, to provide 
information on related research activity. Search engines often allow the user to 
specify phase of research to ensure search results fit within the EAA timeframe 
of interest. Searches can produce large numbers of results, and the results may 
need further investigation to work out if they are relevant. Trial registers may 
also hold information that is out of date. 
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Patent applications 
A patent protects new inventions and describes features of the invention such 
as how it works. You can search published applications at Espacenet 
(http://www.epo.org/searching/free/espacenet.html). However, the amount of 
information available in an application is often limited and it can be difficult to 
determine exactly what the technology is and who it will be aimed at. 
 
Secondary Sources 
Commercial and medical media 
These sources summarise news and developments in health care, health 
research and the health technology industry. There are numerous products 
available electronically, some require a subscription and others are free of 
charge.  
These sources: 
 Provide early information. 
 Vary in the depth of information provided. 
 Often have daily or weekly email alerts. 
 
Potential issues for identification 
 There is overlap between sources. 
 Items can be difficult to follow-up.  
 There are plenty of announcements but not all technologies will eventually 
reach the market.  
 There is a trade-off between completeness and efficiency.  
 
EuroScan - International Network 
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Conference proceedings and scientific journals 
Most learned societies hold regular conferences and sponsor academic journals 
for the presentation and discussion of research findings. Searching through 
relevant conference proceedings and abstracts, and/or a selection of journals 
can provide EAA systems with information on new and emerging health 
technologies and research activities. There are many conferences and journals, 
and an EAA system will need to be selective about those that yield the most 
relevant results. 
Medical societies, for example, American Cancer Society, American Society of 
Haematology, European Society for Medical Oncology, can be a useful source 
for: 
 Information on ongoing clinical trials. 
 Early and preliminary study results.   
 Conference highlights. 
Medical journals, for example, British Medical Journal, JAMA, The Lancet, 
NEJM, and Blood, can be a useful source for: 
 Published trials – although these are often too late for EAA systems. 
 News stories or editorials on emerging health technologies and trends.  
 
Regulatory authorities 
Regulatory bodies such as the European Medicines Agency (EMA), the US 
Food and Drug Administration (FDA) and the Australian Therapeutic Goods 
Administration (TGA) can be used as an identification source. However, 
accessible information on technologies may be too near to launch for some 
EAA systems.  
These sources may provide: 
 An overview of evidence for licensing.  
 Scientific discussions of expert panels, e.g.  
 FDA ODAC – Oncological Drugs Advisory Committee 
 EMA CHMP – Committee for Medicinal Products for Human Use 
 EMA COMP – Committee for Orphan Medicinal Products 
 EMA CAT – Committee for Advanced Therapies.  
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 Alerts on pending decisions.  
 Withdrawals and rejections  
 This information can allow EAA systems to remove technologies from their 
monitoring lists. 
  
Experts and identification 
Engaging with relevant experts to identify new or emerging technologies can be 
very productive. 
 Experts will have relevant experience and knowledge of: 
 Clinical practice, 
 Research – ongoing and past, 
 Conferences and journals. 
 Patients’ characteristics, 
 Infrastructural requirements.  
 
Tertiary Sources 
Other EAA systems 
Many EAA systems have a website where they publish their non-confidential 
outputs. In addition, EuroScan members enter information on new and 
emerging technologies they have identified and/or prioritised into the EuroScan 
database of new and emerging health technologies. Full access to this 
database requires membership of EuroScan but many of the fields are available 
to general users via the EuroScan website (www.euroscan.org.uk) providing 
basic information on these technologies. 
A list of sources used for identification of new and emerging technologies can 
be found in Appendix 5. This list is not exhaustive and new identification 
sources frequently emerge. 
 
EuroScan - International Network 
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Stage 4: Filtration  
At the filtration stage, technologies found at the identification stage are 
considered and by applying pre-set criteria, technologies that are relevant to 
your EAA system and stakeholder are selected. Filtration facilitates the best use 
of available resources. 
 
General  
 It is necessary to obtain some information about the technology to inform the 
filtration process. 
 A filtration form can be developed to ensure consistency of information 
collected and application of filtration criteria.  
 The filtration step should take into account the interests of stakeholders and 
the time horizon, and will thus be health system dependent. 
 Organisational, ethical, legal and social aspects should be considered at this 
stage. 
 
Questions to be asked at filtration 
Is the technology in the system’s remit?  
 Is the technology relevant to the healthcare system?  
 Most healthcare systems have disease and healthcare priorities where 
funding and research will be targeted at. This may influence which 
technologies are filtered in for further investigation. 
 Is the technology new, equivalent to existing technologies or is an 
established technology intended for a new indication?  
 Some EAA systems may only focus on new technologies whereas others 
may be required to capture information on generic drugs.  
 Innovation may be used as a filtration criteria but it can be difficult to 
decide if a technology is innovative early in the development cycle or when 
there is a paucity of information. 
 Is the technology within the timeframe of interest? 
 This may vary depending on technology type. 
 Does the technology have potential to impact on the healthcare system?  
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 Even with limited information it may be possible to determine if a 
technology has the potential to have an impact e.g. clinical benefit, safety, 
impact on patients (convenience), costs or on infrastructure (staffing, 
equipment etc.). 
 
Figure 4: Possible framework for filtration 
New technology 
identified  
Further research 
(contact expert) 
Further research 
(contact developer) 
 
EAA output  
Exclude topic from 
database 
Further research 
(expert, company, 
searches) 
Topic excluded from 
database 
Innovative? 
Impact? 
In timeframe? 
 
Not sure 
Not sure 
Not sure 
No 
No 
No 
Yes 
Yes 
Yes 
Too early – monitor 
Too late – exclude 
topic from database 
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Stage 5: Prioritisation  
Once technologies relevant to the EAA system have been filtered, the 
remaining technologies can be prioritised according to the system’s capacity for 
assessment or evaluation of the technologies and customer requirements. It is 
recommended that consideration be given to the construction of a set of pre-
defined prioritisation criteria based on stakeholder and customer requirements.  
Technologies must satisfy one or more of these threshold criteria before being 
accepted for further consideration. 
Some agencies are commissioned to assess all new or emerging health 
technologies proposed as the prioritisation has been or will be undertaken by 
stakeholders. As with filtration, further information about a technology may be 
required to enable its prioritisation. This is particularly important if prioritisation 
involves external individuals or a committee. 
 
Methods  
Prioritisation can be carried out in a number of ways depending on resources 
and time available, transparency of process and who is involved: 
 Prioritisation without use of criteria – often staff working in an EAA are 
able to prioritise the more significant technologies based on prior knowledge 
of other technologies (organisational memory) and awareness of policy 
related priorities. This method is the least resource intensive but also the 
least transparent. However, it may be appropriate for some systems. 
 Pre-defined prioritisation criteria that a technology must meet. These may 
include:  
 Burden of disease: 
- Number of patients or size of group – prevalence, incidence. 
- Disease characteristics - severity, duration i.e. acute or chronic, 
mortality, morbidity and service use. 
- Current therapeutic or management options for the patients. 
 Potential impact on: 
- Patients - impact on morbidity, mortality, quality of life, diagnosis, safety, 
compliance vs. current treatment(s). 
- Costs – increased costs or savings, large capital outlay, direct and 
indirect costs for patients and society. 
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- Services and organisations - increased or decreased use, service 
reorganisation, structural changes, staff training requirements, learning 
curves, quality assurance procedures, safety concerns e.g. radiation 
compliance. 
- Societal and legal issues - ethical issues, controversial method or highly 
invasive. 
- Research and development - impact on improving current or 
development of alternative approaches for a given health problem. 
 Potential for inappropriate diffusion given available evidence: 
- Too fast, too slow or misuse.  
 Other: 
- Possible launch date. 
- Is the technology in development for other indications? 
- Are there other technologies in development for the same indication? 
 Scoring tools – prioritisation criteria can be values allocated to technologies 
where only those progress to the assessment and evaluation stage if they 
score above or below a certain threshold.  
 Statistical methods - a method called Best Worst Scaling (BWS) has 
recently been applied to EAA activities to prioritise new or emerging 
technologies that have been identified.  
See Appendix 6 for examples of prioritisation methods, criteria and scoring 
tools. 
 
Who prioritises? 
Prioritisation can be carried out by: 
 Experts – these may be clinical, scientific and/or those involved in HTA: 
 in-house using internal expertise;  
 individual external experts; 
 permanent or ad hoc committees of external experts. 
 Health service decision makers or other users of EAA information.  
 Patients and patient groups. 
Due to a potential conflict of interest, prioritisation does not usually involve 
industry or commercial developers or clinicians and researchers who work 
closely with a technology.  
EuroScan - International Network 
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Stage 6: Assessment  
Assessment of a technology or prediction of potential for impact will depend on 
stakeholders’ interests and needs.  
Types of Assessment  
Assessment may be: 
 Rapid: Taking 24-36 hours to complete, producing a 1-2 page brief overview.  
Rapid assessments are usually conducted in response to a specific request 
from a stakeholder about an emerging technology. 
 Brief: A more detailed but still brief overview taking approximately 0.5-2 
weeks to complete and around 4 - 6 pages in length. Includes background 
information on the technology, how it works, clinical burden of disease, 
current comparator(s), safety and effectiveness data, costs and social, ethical 
and legal concerns. 
 In-Depth: Taking approximately 4-6 months to complete, can be longer than 
40 pages. Not a systematic review but a focused assessment using a 
structured search strategy.  
 
Methods 
It is recommended that an assessment template is developed which will remain 
unchanged for all assessments. The fields (or a selection of the fields) in the 
EuroScan database form the basis of a template for many EAA systems: 
 Technology related information: name, description, mode of administration, 
dose range, company or developer, stage of development, type (i.e. drug, 
device etc.), use (i.e. therapeutic, diagnostic etc.), licensing/reimbursement 
plans. 
 Patient and setting related information: indications, specialty, patient 
numbers, setting for technology use, current management, alternative or 
complementary treatment options.  
 Evidence and policy: clinical evidence and safety; ongoing research; 
ongoing or planned HTA. 
 Impact predictions: health; predicted diffusion; cost, infrastructure and 
economic consequences; ethical, social, legal, political and cultural impact. 
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A search strategy should be developed to ensure consistency of retrieving 
relevant information – the comprehensiveness of the search will depend on the 
product i.e. rapid, brief overview or in-depth report, and the content of the final 
report. Sources for searching may include: 
 Databases on ongoing clinical trials.  
 Commercial pharmaceutical databases.  
 Registration and licensing sites.  
 Relevant scientific conferences. 
 Bibliographical databases.  
The basic criteria for elaborating evidenced-based information may also be 
applicable to early assessments. Thus, if possible it is recommended to specify 
criteria for selecting studies, quality assessment and grading level of evidence. 
 
Involvement of companies and developers 
Basic information about a technology can usually be found on company 
websites, in commercial databases and through general internet searches. 
However to obtain detailed information about a technology such as 
development status, regulatory or marketing plans, unpublished or ongoing 
studies and pricing information, it is usually necessary to contact the developer 
directly.  
It can be helpful to have a standard information request document that is sent to 
companies that sets out the purpose of the information request and the 
questions the EAA system needs answers to. The document should also ask 
the company to clearly mark any confidential information they are providing.  
EuroScan’s position statement on working with industry can be found on the 
EuroScan website - http://euroscan.org.uk/activities/postion-paper-on-industry/ . 
 
Involvement of experts 
Some agencies use scientific and clinical experts to provide information and 
advice during the assessment process. Experts may be aware of ongoing 
clinical trials and will have a good overview of the latest ‘noise’ in their area of 
interest. 
It is recommended to involve, if possible, more than one expert in contributing to 
the output to ensure that a range of views are considered. It is important to 
establish if an expert has any conflicts of interest at the outset of the process. 
EuroScan - International Network 
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Scientific uncertainties  
Depending on its format, the assessment may also include a section on 
scientific uncertainties or knowledge gaps. This section can include a 
description of what the uncertainty encompasses, and what kind of research is 
needed to fill the gap in the future.  
It is important to raise awareness and to clarify the evidence and its limitations 
to both decision makers and those allocating resources in healthcare, as well as 
to carers and patients.   
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Stage 7: Peer review  
Although peer review is placed here at Stage 7, it may also be employed at 
earlier stages in the process, for example, to confirm prioritisation outcomes or 
to validate the general work plan. In theory, peer review can be placed even at 
different stages of assessment including checking methodological accuracy of 
the process, data accuracy, and answers to the research questions defined. If 
placed at this stage, peer review is used to check for quality and accuracy of the 
EAA outputs. 
Peer review can be performed both internally and externally. 
 
Internal review  
WHY:  Internal review can be performed, even on the earliest drafts, mainly to 
check the methodological issues of the assessment (methodological internal 
audit). 
WHO:  Ideally it should be performed by experts in the organisation or agency 
that have not been involved in the assessment; they should also be able to give 
guidance and advice to the authors before the final draft is finalised. 
 
External review 
WHY:  External review can be performed mainly to check the accuracy of data 
and information as well as to get comments and amendments by stakeholders 
on the assessment before publication. 
WHO:  It could be performed by: 
 Group of experts (collaborating with the EAA system occasionally or on a 
regular basis) and/or 
 Clinical experts (appointed to collaborate for the specific assessment as 
having experience with the technology or in the field), 
 Manufacturers of the technology or industry representatives (involved or 
not, at different stages, according to the EAA system), and/or 
 Patients or patient representatives. 
Once the reviewer comments have been collected, these should be considered 
and discussed internally. Further consultation with the reviewers may be 
possible if clarification is needed. The decision to include or disregard the 
changes, as well as the answers to all the comments, may be provided to 
reviewers.
EuroScan - International Network 
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Stage 8: Dissemination 
A dissemination strategy is of vital importance to an EAA system to ensure that 
the information produced is reaching the correct audience at the right time. 
Dissemination will depend on the needs of target groups and stakeholders. A 
structured method of dissemination should be put in place (Figure 5). 
 
Figure 5: Steps in report dissemination 
DEFINE TARGET GROUPS  
• Clinicians (individuals, specialty/ 
professional organisations) 
• Patients/consumers (individuals, 
organisations) 
• Provider organisations (hospitals, 
clinics, managed care organisations) 
• Government policymakers 
(international, national, state, local) 
RESTRICTED PUBLICATION 
• Third party payers 
(government, private sector) 
• Quality assurance and 
utilization review 
organisations 
• Biomedical researchers 
• HTA organisations 
• Research funders 
• Industry 
• News professionals (popular and 
scientific/professional journalists and 
editors)  
• Academic institutions (schools, 
continuing professional education 
programs) 
• General public 
DEFINE CIRCULATION 
WIDE RELEASE LIMITED RELEASE 
PATIENT ORIENTED 
IMPLEMENTATION STRATEGIES 
PUBLIC ORIENTED INSTITUTION ORIENTED CLINICIAN ORIENTED 
EVALUATION OF REPORT DISSEMINATION 
BUDGET 
ALLOCATE RESOURCES 
MATERIALS PERSONAL 
PRINTED 
• Newsletter 
• Report 
• Summary sheet 
• Journal article 
 
DEFINE MEDIA 
WORD OF MOUTH 
• Joining and actively 
participating in 
EuroScan activities 
• Others? 
ELECTRONIC 
• Established email list (possibly automated 
list, RSS feeds?) 
• Website – report, newsletter 
• Web-based database 
• Social media  
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Stage 9: Updating information  
Not all EAA systems update information once a report has been completed on a 
new or emerging health technology. Due to the nature of early assessments the 
information used can is often incomplete and dynamic and is likely to change or 
expand before the technology is fully implemented. In some cases information 
is updated and fed back to customers. On other occasions, it is necessary to 
consider re-assessments to include new information. 
 
Information can be updated: 
 When stakeholders have a specific interest in the technology or are waiting 
for new studies to see what happens with a promising but not yet approved 
technology. 
 When additional results of studies or data collection from monitoring systems 
for new and emerging technologies become available. 
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Stage 10: Evaluation of EAA methods & 
systems 
Evaluation of EAA activities and systems is a logical and necessary step for 
systems that have been functioning for some time. Besides tailoring the EAA 
activities more specifically to the needs of the target group, evaluation also 
allows optimization of resources allocated to the EAA system.  
Evaluation should not be thought of as a single event but rather a progressive 
activity that can take place in several dimensions:  
 
Structure 
Although structural prerequisites are difficult to change, it may be worthwhile to 
question the basics of the EAA system to identify and assess issues that may 
prevent or hinder the system from meeting its objectives. Questions asked may 
cover:  
 Funding – is it sufficient to enable aims to be achieved? 
 Governance and mandate – aims, values and codes of practice, steering 
groups? 
 Place in policy making process – is it integral or trying to influence? 
 Independence from commercial, political or other influence? 
 Staffing – numbers, experience and skills? 
 Facilities – information systems, access to information, access to experts? 
 Ethos within system to review quality and to measure achievement of aims? 
 
Process 
Within a given structure, the way available resources are used and handled will 
determine the outputs and impact of EAA systems. Besides generic 
management processes such as responsiveness to funder requests, reaction to 
changes in the wider policy context or financial management, activities 
specifically related to the EAA system can be evaluated. These include: 
 System accuracy 
 Accuracy of identification and reporting e.g. sensitivity and specificity; 
missing blockbusters and false positives. 
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 Accuracy of predictions e.g. technologies, timeframes, diffusion and 
impact. 
 Timely identification of topics e.g. the use of high-quality sources, the number 
of new topics identified. 
 Application of explicit and agreed identification criteria. 
 Application of explicit and agreed filtration and/or prioritisation criteria. 
 Application of agreed investigation and reporting methods e.g. timeliness, 
quality sources, use of experts, peer review. 
 Timely updating of information systems e.g. licensing plans, expert contact 
details, outputs from system. 
 
Outputs 
The direct outputs of EAA systems, the assessments or predictions of impact, 
differ considerably between systems. Several characteristics can be used to 
describe these assessments, characteristics which can also serve as evaluation 
criteria. Besides assessments, indirect outputs such as workshops or 
publications related to EAA activities can be considered for an evaluation.  
 
Direct – Assessments 
 Number & type 
 Relevance to (key) users  
 Quality  
 Readability and appropriate style. 
 Based on available evidence. 
 Accuracy. 
 Format and consistency in structure and content. 
 Timeliness.  
 Independence and bias. 
 Accessibility  
 ‘Reach’ to other users – professionals, patients, patient groups, other 
decision makers. 
 Coverage across patient groups or priority themes. 
EuroScan - International Network 
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Indirect/other 
 Workshops, presentations and training delivered.  
 Visitors and callers wanting information.  
 Student placements.  
 Publications. 
 
Impact 
The most important question is whether the system achieves what it has set out 
to do, whether the target audiences’ interests and needs have been met and if 
the information provided proved useful. Evaluations can be about the: 
 Acceptance of agency or products 
 Awareness of agency;  
 Satisfaction with agency or products;  
 Agency’s credibility and respect. 
 Utility (use) of information  
 Change in awareness;  
 Change in knowledge;  
 Information considered by decision makers; 
 Information has influenced the decisions taken. 
 
Methods for evaluation 
For each dimension and aspect of EAA activities and systems being evaluated, 
specific standards or measures of success will need to be developed and 
suitable evaluation tools employed. The diversity of dimensions and aspects of 
activities and systems that can be evaluated, lead to a range of tools to be 
considered. Depending on the resources available and the objective(s) of the 
evaluation, a combination of different methods will often yield the most 
comprehensive picture. Example tools and methods include: 
 Internal audit 
 Presence of agreed procedures and processes for identification, filtration, 
prioritisation and/or assessment. 
 Adherence to internal procedures and processes. 
 Presence of policies, for example, on handling of confidential information. 
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 Questionnaires, interviews and focus groups  
 Depending on the dimension being evaluated the target groups can range 
from decision makers e.g. clinical, financial, political; experts e.g. 
researchers, health professionals, technology-specific and patients; 
employees of the EAA system; to other stakeholders such as 
manufacturers. 
 Questions may be around readability, accuracy, timeliness, accessibility, 
satisfaction and use of information from EAA system. 
 Measuring access to EAA system outputs 
 Counting requests for EAA system assessments can give an estimate on 
the acceptance and utility of the EAA. 
 There are programmes that can analyse Internet downloads, from simple 
programmes with only numerical download counts to more sophisticated 
systems which allow differentiation of user’s nationalities. 
 For more refined questions combining download analysis with brief 
surveys e.g. asking 1 or 2 further questions prior to allow downloads can 
help in clarifying whether the target audience of the system uses the 
outputs of an EAA and also which other groups are reached. 
 Analysis against external information sources  
 Audit of responsiveness of EAA system to the publication of new 
information, on for example licensing plans, on company or other routine 
websites. 
 Sources such as licensing agencies, registries or the EuroScan database 
are valuable sources to substantiate system accuracy by cross-checking, 
for example, if all drugs licensed by the European Medicines Agency or if 
all technologies appraised by a national HTA agency have previously been 
identified and prioritised by the EAA system. 
 Content analysis  
 Scrutiny of documents used by policy making bodies can show if the 
information from an EAA system has been considered or used in policy 
making, or incorporated into policy documents. 
 Observation of media coverage may indicate the acceptance and 
awareness of the agency, the accuracy of the system e.g. public debate 
on certain block busters, and may also be used for measuring indirect 
outputs such as workshops or presentations.  
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Appendices 
Appendix 1 - EuroScan member agencies  
Agencia de Evaluacion de Tecnologias Sanitarias (AETS), Madrid, Spain 
Agencia de Evaluación de Technologías Sanitarias de Andalucía (AETSA), 
Seville, Spain 
Agenzia Nazionale per I Servizi sanitari Regionali (Age.na.s), Rome , Italy 
Assistance Publique-Hôpitaux de Paris, Committee for Evaluation and Diffusion 
of Innovative Technologies, France (CEDIT) 
Australia and New Zealand Horizon Scanning Network (ANZHSN)/Health Policy 
Advisory Committee on Technology (HPACT) 
Basque Office for Health Technology Assessment (Osteba), Spain 
Canadian Agency for Drugs and Technologies in Health (CADTH) 
Deutsches Institut fur Medizinische Dokumentation und Information (DIMDI) 
Division of Medical Technology Policy (DMTP), Ministry of Health, Israel 
Health Council of the Netherlands (GR) 
Horizon Scanning Center for Innovative Global Health Technology (H-SIGHT), 
National Evidence-based Healthcare Collaborating Agency, NECA, Korea 
HTA Reviews and Dissemination Department, Norwegian Centre for Health 
Services Research (NOKC) 
Institut national d’excellence en santé et en services sociaux (INESSS), Canada 
Italian Horizon Scanning Project (IHSP) 
Ludwig Boltzmann Institute for HTA (LBI-HTA), Austria 
NIHR Horizon Scanning Centre (NIHR HSC), England  
Swedish Council on Technology Assessment in Health Care (SBU) 
Swiss Federal Office of Public Health (SFOPH) 
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Appendix 2 - Glossary 
Healthcare technology: encompasses all methods used by health 
professionals to promote health, prevent and treat disease, and improve 
rehabilitation and long-term care. These methods include pharmaceuticals, 
devices, diagnostics, procedures (and technologies used as part of a 
procedure), programmes, settings, and public health activities. 
Horizon scanning (health technologies): The systematic identification of new 
and emerging health technologies that have the potential to impact on health, 
health services, and/or society. The methods used can also identify health 
technologies that are becoming obsolete.  
Early awareness and alert (EAA) systems (also known as early warning 
systems or horizon scanning systems):  A system that aims to identify, filter 
and prioritise new and emerging health technologies, or new uses of existing 
interventions; to assess or predict their impact on health, health services and/or 
society; and to disseminate information. 
An EAA system focuses on health technologies that are:  
 new and emerging: A technology that has not yet been adopted in the 
healthcare system. Emerging pharmaceuticals are at the phase II or III 
clinical trial, or pre-launch stage. Emerging medical devices are at the pre-
marketing stage. New health technologies are generally in the launch, early 
post-marketing or early diffusion stages, 
 represent a change in indication or use of an existing technology, or  
 are part of a group of developing technologies that, as a whole, may have an 
impact.  
 
For further related terms see the HTA glossary 
http://htaglossary.net/HomePage  
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Appendix 3 - Examples of EAA networks and 
collaborations 
 
International Networks and Collaborations 
EuroScan International Network 
See www.euroscan.org.uk  
 
Ludwig BoItzmann Institute for HTA (LBI-HTA) and Italian Horizon Scanning 
Project (IHSP) 
LBI-HTA and IHSP have collaborated to produce a number of Horizon Scanning 
in Oncology reports 
See http://hta.lbg.ac.at/page/horizon-scanning-in-der-onkologie-berichte  
The agencies both produce reports on oncology drugs and have a similar time 
horizon for reporting information.  
 
Regional Networks and Collaborations 
Canadian Network for Environmental Scanning in Health 
In 2011, Canada established a country-specific horizon scanning network: the 
Canadian Network for Environmental Scanning in Health (CNESH). CNESH is a 
voluntary network of academics, researchers, clinical experts and decision 
makers representing national and provincial healthcare perspectives. The 
primary objectives of CNESH are to identify innovative health technologies, 
promote horizon scanning methodologies and facilitate information-sharing 
opportunities across Canada. Such opportunities are currently lacking in this 
field and this is likely due to the decentralized nature of Canada’s healthcare 
system; which is characterized by 10 provinces and three territories that deliver 
healthcare independently of each other. CNESH’s work is intended to inform 
decision makers (patients, providers and policy makers) and HTA producers at 
the federal, provincial, regional and local level of Canada’s healthcare system. 
 
Grupo de Evaluación de nuevas Technología Sanitarias 
GENTecS (Grupo de Evaluación de nuevas Technología Sanitarias) was 
established in 2006 as a collaborative network of agencies and organisations 
that had established systems for identifying and/or evaluating new and 
emerging health technologies. The agencies that currently form the network are 
AETS (Agency for Health Technology Assessment, Instituto de Salud Carlos III), 
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AETSA (Technology Assessment Agency Health Andalusia), AVALIA-T 
(Technology Assessment Agency Health Galicia) and Osteba (Technology 
Assessment Service Health of the Basque Country). All of the agencies are 
regional agencies, except AETS which is national. The goal of the network is to 
identify, filter, prioritise and evaluate new and emerging health technologies that 
may have a significant impact on their health systems. Specific objectives 
include sharing methodology and improving the identification process. Each 
agency focuses on specific identification sources to avoid duplication.  
EuroScan - International Network 
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Appendix 4 - Hospital-based EAA systems and 
activities 
Hospitals and in particular university hospitals are typically the point of entry 
and the first adopters of new and innovative technologies. EAA activities in a 
hospital setting can: 
 Take place in close contact with potential users of health technologies and 
especially the medical profession that often signals new technologies in their 
fields; 
 Benefit from hospital specific information extracted from different IT-systems 
such as diagnostic resource groups (DRGs), prescription and registries such 
as cancer registries; 
 Interact with teaching and research communities at the hospital: researchers 
indicating new or emerging technologies and conversely topics of research 
emerging from EAA activity. 
Typically, there is an abundance of technologies to detect and assess with a 
high level of noise, i.e. a significant quantity of irrelevant and low quality data 
and technologies.  
Horizon scanning (identification) is followed by the filtration and prioritisation 
stages in which only the technologies with a potential impact are retained for 
further consideration and assessment. Filtration and prioritisation criteria for the 
assessment to be performed will reflect the hospitals priorities and interests.  
 
Hospital-based assessment 
 Hospital-based HTA addresses context specific issues which are useful in the 
local decision making process. 
 Certain health technologies and in particular some medical devices are not 
routinely assessed at the national level. Instead the hospital has to perform 
the assessment by itself prior to the purchase, implementation and use of 
these technologies. 
 When national evaluation exists, the conclusions and recommendations are 
often too general and do not address hospital selection criteria. Hospitals 
may not find all the answers needed for the local context and their specific 
needs.  
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 University hospitals need to assess technologies which may never diffuse in 
general usage, such as those intended for rare diseases, salvage therapy or 
last-line therapeutics. 
 Hospitals have a direct medical, economic or organisational interest in having 
technologies assessed as soon as possible. 
 Technologies are assessed at a point where little information is available. 
However, a possibly provisional decision needs to be taken. Therefore 
assessment methods have to be adapted specifically to this process. 
 Hospitals may in some cases collaborate with national or regional HTA 
agencies. 
In conclusion, hospital-based HTA enables local decision makers and 
healthcare providers to provide access to quality care, use available resources 
optimally and ensure rapid access to innovations and effective healthcare.  
 
Examples of hospital based EAA systems include CEDIT (Assistance Publique 
– Hôpitaux de Paris). 
Also see the EU funded project AdHopHTA (Adopting Hospital based HTA in 
the EU) http://www.adhophta.eu/   
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Appendix 5 - Identification sources 
The table below contains examples of sources used by EuroScan member 
agencies to identify new and emerging health technologies. It is not a 
comprehensive list of identification sources nor does inclusion indicate that the 
source is endorsed by EuroScan member agencies. 
Source Details and examples Pharmaceuticals1 
MedTech
2 
Other 
Commercial 
Developers 
Contact individual 
companies or trade 
associations. Company 
websites often have 
pipeline information.   
   
Clinical trial registers ClinicalTrials.gov    
 WHO International Clinical 
Trials Registry Platform 
   
 Current Controlled Trials    
 EU Clinical Trials Register    
Patent applications European Patent Office    
 UK Intellectual Property 
Office 
   
Commercial and 
medical Media 
PharmaTimes     
 Reuters Health – 
subscription required 
   
 PMLiVE     
 Scrip Intelligence - daily 
news, subscription 
required 
   
 Medgadget     
 Clinica MedTech 
Intelligence  - daily news, 
subscription required 
   
 Fierce Medical Devices    
                                               
1
 Includes drugs, biologics, biotechnology etc. 
2
 Includes devices, diagnostics etc. 
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Source Details and examples Pharmaceuticals1 
MedTech
2 
Other 
 AdvaMed SmartBrief (US)    
 ECRI Institute – subscription 
required 
   
 Medical News Today (daily 
RSS) 
   
 Medical Design technology    
 Medical Device Network    
 www.implantable-
device.com  
   
General media BBC news (Health)    
Conference 
Proceedings 
American Society of Clinical 
Oncology (ASCO) 
   
 European Society for 
Medical Oncology (ESMO) 
   
Scientific Journals Nature Reviews Drug 
Discovery 
   
 Nature Medicine – may be 
early scientific research 
   
 British Medical Journal    
Regulatory 
authorities 
EMA –medicines under 
evaluation 
   
 EMA – orphan drugs    
 EMA-Committee for 
Advanced Therapies 
   
 US Food & Drug 
Administration 
   
 Therapeutic Goods 
Administration 
   
Horizon Scanning 
Databases/websites 
EuroScan    
 Agency for Healthcare 
Research & Quality (AHRQ) 
(US) 
   
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Appendix 6 - Prioritisation: Examples of methods, 
criteria and scoring systems 
LBI-HTA Prioritisation Form 
Drug XY 
Are there already other treatment regimen(s) 
available for this specific indication or is this 
drug a completely new therapy? 
Treatment available 
New therapy 
Will the drug replace a current drug regimen or 
is it an add-on therapy? 
Add-on 
Replacement 
New therapy 
Is there potential for a significant health benefit 
to the patient group (high clinical impact)? 
Major 
Minor 
Is there potential for a significant impact on 
drug budget if the technology diffuses widely 
(because of expected moderate to high unit 
costs and /or because of high patient 
numbers)? 
Major 
Minor 
Is there potential for inappropriate use (off-
label) of the technology? 
Major 
Minor 
Choose Category 
Highly relevant – assessment 
Relevant – monitoring 
Not relevant – drop drug 
Expert’s comment(s)  
 
Pri-Tec Tool 
An example of an electronic scoring tool is the PriTec Tool developed by the 
Galician Health Technology Assessment Agency (avalia-T) – 
http://pritectools.es/index.php.  PriTec is a web-based application that can 
compare up to 50 technologies simultaneously. The tool consists of weighted 
prioritisation criteria grouped by characteristics associated with the technology:  
 the target population/end-users;  
 the technology itself;  
 safety/adverse effects; and,  
 costs, organisation and other implications. 
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Best Worst Scaling (BWS) 
BWS is “a measurement method based on a theory of how humans choose the 
two most extreme items in a set of three or more items. BWS assumes that a 
person examines the options in a set, and chooses the pair of options that 
exhibits the largest differences on the underlying subjective scale of interest.”3 
Gallego et al.4 explored the value of BWS in horizon scanning by investigating 
clinicians’ views on emerging technologies that will impact outcomes in 
hepatocellular carcinoma (HCC) in the next 5 to 10 years. The study concluded 
that BWS could be an important research tool to facilitate horizon scanning. 
 
                                               
3
  Flynn TN, Louviere JJ et al, Best-worst scaling: What it can do for health care research and how to 
do it, Journal of Health Economics, 2007, 26:171-189 
4
 Gisselle Gallego, John F.P. Bridges, Terry Flynn, Barri M. Blauvelt and Louis W. Niessen (2012). 
Using best-worst scaling in horizon scanning for hepatocellular carcinoma technologies. International 
Journal of Technology Assessment in Health Care, 28, pp 339-346. 
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Appendix 7 - Selected member publications  
General  
Packer C, Gutierrez-Ibarluzea I, Simpson S. The evolution of early awareness 
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Appendix 8 - EAA checklist 
Stage 1. Identify your market 
1. What is the purpose of your early awareness and alert (EAA) system? 
 
 
 
2. Who do you intend to inform? 
Policy makers  Reimbursement agencies 
Commissioners Health Technology Assessment (HTA) 
agencies 
Purchasers Commissioners of research 
Healthcare professionals Patients 
Healthcare providers (primary and 
secondary care) 
Patient organisations 
National Regional Local 
3. What does your customer expect from you? 
 
 
4. What type of output and information is needed? 
 
 
 
5. What is the scope of your EAAS? 
Pharmaceuticals Surgical interventions Community care/programmes 
Devices Medical procedures Public health interventions 
Diagnostics Hospital care Military medicine 
Other   
Stage 2: Determine your time horizon 
6. When does your customer want information? 
Development of innovation  Introduction into the health system 
Pre-marketing Broad diffusion 
Marketing Other 
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Stage 3: Identification 
7. Identification sources (indicate which sources to be used & list main sources ) 
Source Use Main sources 
Commercial developers  
 
 
 
Clinical trial registers 
 
  
Patent applications 
 
  
Commercial & medical 
media 
  
Conference proceedings 
 
  
Scientific journals 
 
  
Regulatory authorities 
 
  
EAA systems and horizon 
scanning databases 
  
Experts 
 
  
Other 
 
  
Stage 4. Filtration 
8. Define your filtration criteria (choose and add others to suit EAA system) 
Possible filtration criteria Tick if using 
Is the technology relevant to the health system?  
Is the technology new, equivalent to existing technologies or is it 
intended for a new indication? 
 
Is the technology within the timeframe of interest?  
Other (state)  
Other (state)  
Other (state)  
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Stage 5: Prioritisation 
9. Prioritisation method 
Method Tick if using 
Prioritisation without use of criteria  
Use pre-defined prioritisation criteria  
Use a scoring tool (state which one)  
Other  
10. Who is involved in prioritisation 
In-house using internal expertise   
Individual external experts  
Permanent or ad hoc committees of external experts  
Health service decision makers or other users of EAA information   
Patients and patient groups  
Other  
11. Define your prioritisation criteria (choose and add others to suit EAA system) 
Possible prioritisation criteria Tick if using 
Patient group and associated burden of disease  
Impact on patients  
Impact on costs  
Impact on services and organisation  
Impact on research and development  
Societal and legal issues  
Potential for inappropriate diffusion  
Other (state)  
Other (state)  
Stage 6: Assessment  
12. Type of assessment 
Rapid Brief In-depth 
13. Information included in assessment 
Technology related Evidence  
Patient related Policy 
Safety Impact prediction 
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Stage 7: Peer Review 
14. Who will peer review outputs? 
In-house Methodological experts  
Individual experts  Industry/ the manufacturers 
Group of experts Patients/patient representatives 
Other (state)  
Stage 8. Dissemination 
15. Define target groups and/or stakeholders 
Clinicians Third party payers Industry 
Provider organisations Research funders Journalists 
Policymakers Researchers Academic institutions 
Patients HTA organisations General public 
Others (state)   
16. Define circulation 
Restricted  Limited release Wide release 
17. Define implementation strategy 
Patient oriented Institution oriented 
Clinician oriented Public oriented 
18. Define media 
Printed - newsletter Email list  Word-of-mouth 
Printed- report Website Social media 
Printed – summary  Database Journal publication 
Stage 9: Updating information 
19. Updating strategy 
No updates to be carried out 
Update reports on technologies that are being monitored 
Update reports if significant new information becomes available 
Update reports if requested by customer 
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